Meloxicam injection - CSPC Pharmaceutical Group
Alternative Names: Meloxicam nanocrystal injection - CSPC Pharmaceutical GroupLatest Information Update: 10 May 2024
At a glance
- Originator CSPC Pharmaceutical Group
- Developer CSPC Pharmaceutical Group; CSPC ZhongQi Pharmaceutical Technology
- Class 2 ring heterocyclic compounds; Amides; Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Postoperative pain